fulvestrant has been researched along with Triple Negative Breast Neoplasms in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 7 (70.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harao, M; Hayashi, K; Kitayama, J; Nishida, S; Ogihara, K; Sakuragi, M; Sasaki, Y; Sata, N; Shiba, S | 1 |
| Allen, MC; Flint, MS; Gee, JM; Intabli, H; Oesterreich, S; Qattan, A; Yeoman, MS | 1 |
| Ishiguro, H; Iwakuma, N; Iwamoto, T; Kikawa, Y; Kobayashi, K; Masuda, N; Niikura, N; Oba, M; Okuno, T; Ozaki, S; Saji, S; Tada, H; Takeshita, T; Toh, U; Tsuneizumi, M; Watanabe, K; Yamamoto, Y | 1 |
| Ali, S; Arkenau, T; Bahl, A; Baird, RD; Chalasani, P; Chap, LI; Clack, G; Coombes, RC; Gradishar, W; Howell, S; Jeselsohn, R; Kenny, L; Krebs, MG; Lord, SR; Mansi, J; McIntosh, S; Melear, J; Mitri, Z; O'Shaughnessy, J; Palmieri, C; Richards, P; Sardesai, S; Ward, P | 1 |
| Barriga, S; Burdaeva, O; Conte, P; Frenzel, M; Grischke, EM; Hurt, K; Inoue, K; Johnston, S; Kaufman, PA; Koh, H; Llombart-Cussac, A; Lu, Y; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Sohn, J; Toi, M | 1 |
| Exinger, D; Fischbach, C; Herrscher, H; Kalish-Weindling, M; Leblanc, J; Petit, T; Pivot, X; Velten, M | 1 |
| Inoue, K; Ito, Y; Iwata, H; Kawaguchi, T; Llombart-Cussac, A; Masuda, N; Miyoshi, Y; Mori, J; Mukai, H; Nakayama, T; Sakaguchi, S; Sledge, GW; Takahashi, M; Tanizawa, Y; Toi, M; van der Walt, JS | 1 |
| Fredriksson, I; Frisell, J; Haglund, F; Hartman, J; Karthik, GM; Katchy, A; Linder, S; Lövrot, J; Ma, R; Rosin, G; Viberg, L; Williams, C; Zhang, X | 1 |
| Cai, X; Chai, R; Chen, J; Chen, L; Gong, X; Gu, J; Liu, Y; Mo, L; Thiery, JP; Wang, X; Wu, C; Wu, X; Yu, S; Yu, Z; Zhang, J; Zhu, T | 1 |
| Abrahamsson, A; Dabrosin, C; Mishra, AK | 1 |
3 trial(s) available for fulvestrant and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Topics: Administration, Oral; Biopsy; Cyclin-Dependent Kinase Inhibitor Proteins; Cyclin-Dependent Kinases; Enzyme Inhibitors; Fulvestrant; Humans; Triple Negative Breast Neoplasms | 2023 |
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2020 |
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Double-Blind Method; Female; Fulvestrant; Humans; Japan; Middle Aged; Quality of Life; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2021 |
7 other study(ies) available for fulvestrant and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
[Long-Term Survival of a Patient with Triple-Negative Breast Cancer with Hormone Receptor Status Conversion between Primary and Metastatic Tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fulvestrant; Humans; Mastectomy; Middle Aged; Triple Negative Breast Neoplasms | 2022 |
Glucocorticoid induced loss of oestrogen receptor alpha gene methylation and restoration of sensitivity to fulvestrant in triple negative breast cancer.
Topics: Animals; DNA Methylation; Estrogen Receptor alpha; Fulvestrant; Glucocorticoids; Humans; Hydrocortisone; Mice; Triple Negative Breast Neoplasms | 2023 |
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Fulvestrant; Humans; Japan; Receptor, ErbB-2; Receptors, Estrogen; Triple Negative Breast Neoplasms | 2023 |
Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Fulvestrant; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyridines; Retreatment; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Proliferation; Estradiol; Estrogen Receptor beta; Female; Fulvestrant; Gene Knockdown Techniques; Glycolysis; Humans; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Phenotype; Pyrazoles; Pyrimidines; Spheroids, Cellular; Tamoxifen; Triple Negative Breast Neoplasms; Tumor Burden; Up-Regulation | 2017 |
Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Topics: Acetylation; Anilides; Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Cell Cycle; Cell Line, Tumor; Cell Survival; Estradiol; Female; Fulvestrant; Histone Deacetylase 6; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Immunohistochemistry; Lactams, Macrocyclic; Mice; Tamoxifen; Triple Negative Breast Neoplasms | 2017 |
Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; Drug Synergism; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Prognosis; Steroids; Tamoxifen; Triple Negative Breast Neoplasms; Up-Regulation | 2016 |